PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

By M. Roemer, R. Advani, A. Ligon, Y. Natkunam, R. Redd, H. Homer, Courtney F Connelly, Heather H. Sun, S. Daadi, G. Freeman and 7 more. Journal of Clinical Oncology, 2016

701 citations recorded by the source corpus.

Subfields: Dermatology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/14da626d49e0d60e007fe0f3ddfcff1a717dc1ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. S. Rajkumar
2. M. Hung
3. J. Hsu
4. Chia‐Wei Li
5. Jong-Ho Cha
6. Li-Chuan Chan

Citations in the corpus

• Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. (2017, neutral): “(%) 4 (2-12) 4 (1-11) 3 (2-10) 4 (1-12) Prior lines of therapy, No.”
• Mechanisms controlling PD-L1 expression in cancer (2019, background): “1, and genomic rearrangements in this region, including amplification and translocation, have been shown to upregulate its expression, leading to enhanced immune escape as reported for cHL, primary mediastinal large B-cell lymphoma (PMBCL), NSCLC, squamous cell carcinoma, and gastric adenocarcinoma ”
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (2022, background): “While the basic description has not changed substantially since the last century, WHO-HAEM5 includes a comprehensive section on the etiology and pathogenesis of CHL, in particular incorporating new data on the crucial role of the microenvironment in modulating the disease [172, 173].”